DPP-CNDAC
Latest Information Update: 17 Aug 2001
Price :
$50 *
At a glance
- Originator Sankyo
- Class
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Aug 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 05 Feb 1999 New profile
- 05 Feb 1999 Preclinical development for Cancer in Japan (Unknown route)